This retrospective cohort study reviewed records from 113 patients with primary tinnitus at a single centre. Forty-six patients received ultrasound-guided stellate ganglion block (SGB) alone as the control group, while 67 received SGB combined with a medication regimen. Researchers compared tinnitus severity scores, quality of life across multiple domains, psychological outcomes, adverse events, and patient satisfaction between the two groups.
The combined group showed statistically greater improvements across all tinnitus severity metrics, quality-of-life domains (physical, emotional, role, cognitive, social), and psychological outcomes (anxiety, depression, stress, sleep, social support). Rates of adverse events including headache, dizziness, and nausea were similar between groups. Patient satisfaction was higher in the combined group, though fewer patients in that group reported being “very satisfied” specifically.
The study’s authors explicitly note that the retrospective observational design means only associations can be established, not causal relationships. The two groups were not randomly assigned, baseline differences not captured in the record review could confound results, and the sample sizes are modest (46 and 67 patients). The specific medications used in the combination arm are not detailed in the abstract, making it difficult to evaluate which component drives the additional benefit. A prospective randomised controlled trial is the necessary next step to determine whether this combination genuinely outperforms SGB alone and to establish the relative contributions of each treatment component.
What This Means for You
Stellate ganglion block is a nerve block procedure not yet established as a standard tinnitus treatment. This small retrospective study suggests that combining it with medication may offer more benefit than the nerve block alone, but the evidence is preliminary. Patients curious about this approach should discuss it with an otolaryngologist or pain specialist, and should be aware that randomised trial evidence is currently lacking.